{"groups":[{"description":"The usual adult dosage for oral administration was 4 mg as ixazomib, in the fasting state, once a day, once a week for 3 weeks (Days 1, 8, and 15), with a 13-day washout period (Days 16 through 28). This 4-week cycle was repeated for 6 cycles. The dose might be reduced appropriately according to the patient's condition. Participants received interventions as part of routine medical care.","id":"FG000","title":"Ixazomib 4 mg"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"32"}],"type":"Protocol Violation"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"774"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"742"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"32"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Participants with a historical diagnosis of relapsed/refractory multiple myeloma were enrolled. Participants received ixazomib as part of a routine medical care.","recruitmentDetails":"Participants took part in the survey at 316 investigative sites in Japan, from 24 May 2017 to 8 March 2022."}